AblePay closes a $20 million Series A led by F-Prime
AblePay closed a $20 million Series A led by F-Prime to scale non-recourse patient payments. The round funds hospital distribution, not a patient loan book.
AblePay is not raising a loan book. On October 7, 2026 the Allentown firm said it had completed a $20 million Series A led by F-Prime, with A1 Health Ventures and .406 Ventures participating, for growth, a deeper platform, and more health systems. PayZen's August 2024 round was a different instrument: a $32 million Series B led by New Enterprise Associates, plus a $200 million warehouse from Viola Credit to pre-fund care-now-pay-later plans. AblePay's wire discloses no credit line. The $20 million buys distribution. Payment within 14 business days, with no recourse, comes from the discount the hospital accepts.
One side holds the receivable and funds it with debt. The other buys the bill at a negotiated rate and gives part of the concession back. AblePay is the second model, and F-Prime has just led the equity.
What F-Prime is buying
"Healthcare affordability affects both sides of the bill," Founder and CEO John Fistner said in the October 7 release. Patients need a way to manage the cost. Providers need to collect revenue already earned. Only a fraction of that burden, he said, is served by any third-party financing solution. Nikhil Marathe, principal at F-Prime, called the model differentiated for both sides.
The same release describes A1, in Chicago, as backed by health-system limited partners with more than 110 hospitals and over 15 million patients a year, and .406, in Boston, as managing over $1.3 billion. Neither number is an AblePay valuation. The wire gives no post-money figure, and the company news page still ends in November 2022.
A discount, paid in 14 business days
AblePay's provider page says it takes the balance and sends a guaranteed non-recourse payment, at a discount, within 14 business days of a claim. Enrollment is free. Patients can be eligible for 13% off, with zero interest, fees, or penalties, and the page says credit scores are untouched. It cites a Net Promoter Score of 69, and it says integration is same-day.
PayZen is selling the other model
PayZen has not named AblePay in a reply. On February 4, 2026 it said KLAS Research had named it the 2026 Best in KLAS winner for patient financing. In that release it reported threefold revenue growth in each of the past three years, a 30% average collections lift, and a 13% bad-debt reduction, with a patient Net Promoter Score of 71 against an industry average of 45. TechCrunch reported that the 2024 equity sat next to the warehouse so the plans could be funded. AblePay's release does not describe borrowing against a loan tape.
The $591 billion line is a forecast
The release says that, according to the Centers for Medicare & Medicaid Services, Americans paid $591 billion out of pocket in 2025, up 6%. Table 3 of the actuaries' projections workbook, issued with the June 24, 2026 fact sheet, shows $591.1 billion for 2025, up 6.2%, and labels the year projected. The workbook puts the last historical line at 2024, when out-of-pocket spending rose 5.9% to $556.6 billion, or 11% of national health expenditure. The rounding is fair. Calling a projection money already paid is not.
Ten years, and a vacated rule
Founded in Bethlehem in June 2016, AblePay is Fistner's second healthcare start-up. The leadership page says he had been chief financial officer and chief operating officer of a hospital network. A June 11, 2026 anniversary release cited endorsements from 21 state hospital associations, four straight Inc. 5000 appearances, and No. 440 in 2025. Fistner said the company often hears that members join for the savings but stay for the advocacy.
A January 7, 2025 Consumer Financial Protection Bureau rule that would have kept medical debt off credit reports was vacated on July 11, 2025. The Bureau's page says the Eastern District of Texas found the rule contrary to the Fair Credit Reporting Act. AblePay, sold as score-neutral, does not use that tradeline as a collection threat.
Distribution is the constraint
This is not a megadeal. As this desk reported, US fintech funding hit $16 billion in the second quarter of 2026 while smaller rounds shrank 17%. REPAY closed a $372 million deal for KUBRA to buy bill-pay scale. Forage raised $40 million for a Supplemental Nutrition Assistance Program payments rail, distribution into a closed system rather than a credit warehouse. AblePay's Series A fits that pattern.
If hospitals give up enough rate to fund a saving of up to 13% and still leave a margin, $20 million covers sales, advocates, and the platform. If they do not, the non-recourse promise has only that spread behind it. A1's hospital backers are the test. F-Prime can introduce the firm. It cannot sign the contracts. PayZen already has the pre-funded plan and the KLAS badge. This round is a vote for the discount.
Reporting by Rick Steves. Filed 12 October 2026, 14:33 GMT.
Senior Reporter, Regulation and Fintech
Rick Steves has seen business and economics through many lenses. He joined the financial services industry in 2009, and has been a financial journalist since 2011.
